|
PHF20L1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.9450000054988E-08 |
| Normal-vs-Stage3 |
1.22124532708767E-15 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
3.248800E-01 |
| Stage1-vs-Stage3 |
1.726030E-02 |
| Stage1-vs-Stage4 |
3.022800E-03 |
| Stage2-vs-Stage3 |
9.939400E-03 |
| Stage2-vs-Stage4 |
1.442480E-03 |
| Stage3-vs-Stage4 |
2.413200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63169477929159E-12 |
| Normal-vs-AfricanAmerican |
3.68319999999311E-06 |
| Normal-vs-Asian |
2.01116900910847E-12 |
| Caucasian-vs-AfricanAmerican |
2.565800E-01 |
| Caucasian-vs-Asian |
9.833800E-01 |
| AfricanAmerican-vs-Asian |
2.924200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
4.169800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62569957495862E-12 |
| Normal-vs-Age(81-100Yrs) |
4.791800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.647600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.803600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.949600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.012600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.238800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.923800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.00529999996968E-07 |
| Classical-VS-Follicular |
2.82259999995205E-06 |
| Classical-VS-Other |
7.424200E-01 |
| Classical-VS-Normal |
1.65945035490722E-12 |
| Tall-VS-Follicular |
5.65358870829868E-12 |
| Tall-VS-Other |
3.120000E-02 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
2.555300E-03 |
| Follicular-VS-Normal |
1.381510E-04 |
| Other-VS-Normal |
2.60850000044499E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.66133814775094E-16 |
| Normal-vs-N1 |
4.19664303308309E-14 |
| N0-vs-N1 |
9.948300E-02 |
|
|
